Breaking News

Financial Report: Charles River Labs

May 1, 2014

Preclinical segment sales up 5% in the quarter

Charles River Labs
 
1Q Revenues: $299.4 million (+3%)

1Q Earnings: $32.4 million (+26%)

Comments: RMS segment sales were $185.6 million in the quarter, up 2%, with growth in the Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $113.8 million, up 5% driven by continued demand from mid-tier biotechnology clients.
blog comments powered by Disqus
  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision

  • The Impact of Sample Handling  and Processing on the Outcome of Bioanalytical Testing

    The Impact of Sample Handling and Processing on the Outcome of Bioanalytical Testing

    Haiko Pillu, Head Technical Operations, Life Science Services, SGS Belgium NV||September 8, 2016
    Optimizing bioanalytical procedures to get reliable results in clinical studies

  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture